Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: HoodBuilder who wrote (804)	1/30/2000 4:03:00 AM
From: JMarcus	Read Replies (1) \| Respond to of 3158

>>The [EPIX] product will replace the need for invasive angiograms in a large number of patients by allowing doctors to view cardio-vascular irregularities through 3D MRI.<< I just listened to the Jan. 22nd Informed Investors presentation by EPIX. I'm very impressed by what I heard. Their product won't just replace angiograms, it will vastly enlarge the market for imaging the cardio-vascular system. The current procedure, besides being invasive, risky (death is actually a risk) and expensive (in terms of the length of hospital care required for the patient), is limited in terms of the area of the cardio-vascular system that can be examined during a single procedure. The EPIX product does not have that limitation--it allows the physician to produce an MRI scan of the entire circulatory system. There is a tremendous advantage in being able to examine the entire circulatory system in a single session. The reason is that a patient who develops plaques in a coronary artery is at heightened risk of having plaques in other arteries as well (e.g., the renal arteries). The ability, using the EPIX product, to allow the physician to examine the entire circulatory system for plaques in a single MRI session will improve health care tremondously by allowing physicians to identify and treat minor plaque problems throughout the body before they erupt into crises. The speaker said the FDA was anxious to replace the current angiogram drug, which is very toxic to the kidneys and must be administered in minute quantities. The EPIX product appears to have no toxic side effects and should (in the speaker's opinion) be a slam dunk for FDA approval. He also claimed that only competitive new products are 5 years behind the EPIX product in development. Marc